Unlike most of the peptides discussed in the English-speaking research community, Selank arrives already carrying a clinical history — one written almost entirely in Russian, and rarely translated in full. This is what the peer-reviewed literature actually says.
What: A synthetic seven-amino-acid peptide derived from tuftsin, a natural fragment of the immune protein IgG, developed in Russia as a non-benzodiazepine anti-anxiety agent.
Research areas: Generalized anxiety disorder · Cognitive performance under stress · Immune and cytokine balance · Neurotrophic gene expression · Benzodiazepine comparison
Evidence: Russian clinical trials in anxiety disorder; extensive rodent behavioral and gene-expression studies; no independent Western Phase 3 replication.
Status: Approved as a prescription medicine in Russia for generalized anxiety disorder. Not approved by the EMA, MHRA, or FDA. Sold as a research chemical elsewhere.
What is Selank?
Selank is a synthetic heptapeptide — a chain of seven amino acids — designed as a stabilized analog of the endogenous immunomodulatory tetrapeptide tuftsin. Tuftsin itself is a naturally occurring fragment of the immunoglobulin IgG, first isolated at Tufts University in the 1970s, which is why it carries the name. In the human body, free tuftsin is rapidly broken down by peptidases, and its biological half-life is extremely short.
To overcome this instability, researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences attached a three-amino-acid extension (Pro-Gly-Pro) to the tuftsin sequence. The resulting heptapeptide is substantially more resistant to enzymatic degradation (breakdown by the body's enzymes) while retaining affinity at the relevant biological targets (Myasoedov et al., 2015).
The molecule's full amino-acid sequence is:
The first four residues (Thr-Lys-Pro-Arg) correspond to the tuftsin core; the trailing Pro-Gly-Pro motif is the stabilizing tripeptide extension. The molecule carries no disulfide bridges and no unusual amino acids.
Origin and development
Selank was developed in the 1990s through a collaboration between the Institute of Molecular Genetics of the Russian Academy of Sciences and the Zakusov Institute of Pharmacology. The scientific program was led principally by Nikolai Myasoedov, whose laboratory had previously been responsible for Semax, and drew on decades of work by Ivan Ashmarin and colleagues on regulatory peptides (Ashmarin et al., 2005).
The explicit design goal was a non-benzodiazepine anxiolytic — a compound capable of reducing anxiety without the sedation, cognitive impairment, tolerance, and dependency liability that characterize traditional GABA-A agonists. The team's interest in tuftsin as a starting point reflected the emerging view that immunological peptides and neural peptides interact far more extensively than the older compartmentalized pharmacology had suggested.
Selank was subsequently approved in the Russian Federation as a prescription medicine for generalized anxiety disorder, administered as an intranasal solution. It is, in other words, not merely a research chemical inside Russia — it is a registered pharmaceutical (Zozulya et al., 2008).
Relationship to Semax
Anyone reading the Russian peptide literature quickly notices that Semax and Selank are siblings. Both were developed at the same institute, both draw on the Myasoedov / Ashmarin tradition of regulatory peptide design, and both are delivered as intranasal solutions. The two compounds are frequently described in the Russian literature as complementary: Semax positioned around cognitive performance and neuroprotection, Selank positioned around anxiolysis and immunomodulation.
In practical terms, Russian clinical writing often presents them as a matched pair — a cognitive peptide and an anxiolytic peptide from the same scientific school. They do not share a sequence, however. Semax is a heptapeptide based on a fragment of ACTH (adrenocorticotropic hormone); Selank is a heptapeptide based on tuftsin. The overlap is programmatic, not structural.
Proposed mechanisms of action
The literature proposes several overlapping mechanisms for Selank. As with most regulatory peptides, these are described as "proposed" deliberately — no single dominant mechanism has been fully established, and the pharmacology is best understood as modulation of several interacting systems.
GABAergic modulation
A consistent finding in the Russian literature is that Selank produces anxiolytic (anxiety-reducing) effects that resemble benzodiazepines in behavioral models, but without the sedative and muscle-relaxant features characteristic of GABA-A agonists. Published work has reported interactions with the GABA-A receptor complex, though Selank does not appear to bind at the benzodiazepine site directly (Semenova et al., 2007).
Cytokine modulation
Several studies from Uchakina and colleagues have reported that Selank administration modulates the balance of pro- and anti-inflammatory cytokines (immune signaling molecules), with effects on interleukin-6 (IL-6) expression among others. This immunomodulatory dimension is one of the features that sets the compound apart from conventional anxiolytics (Uchakina et al., 2008).
Enkephalin system interaction
Research has reported that Selank influences the enkephalin system, including effects on enkephalin-degrading enzymes. Published work has proposed this as one of the mechanisms through which the peptide produces its anxiolytic profile (Kozlovskaya et al., 2003).
BDNF and NGF expression
Gene expression studies from Kolomin and colleagues have reported that Selank administration is associated with changes in the expression of neurotrophic factors, including BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), alongside broader shifts in the hippocampal transcriptome (Kolomin et al., 2011).
Immunomodulatory effects
Tuftsin, the parent molecule, is itself a classical immunomodulator — it was originally described as a phagocytosis-stimulating factor (phagocytosis is how immune cells engulf and destroy pathogens). Selank retains some of this immunological character and has been studied in models of immune dysregulation, with published work reporting effects on leukocyte function and cytokine balance (Kolomin et al., 2013).
Russian regulatory peptide research frequently treats mechanism as emergent rather than reductive — the compounds are described as modulating networks of interacting systems, not as ligands of a single receptor. Readers coming from a Western "one molecule, one target" framing will find the literature harder to parse. "Selank acts through the GABA system" is an oversimplification; the data is more properly read as "Selank influences behavior in GABA-sensitive models, with measurable effects on several interacting systems."
Key research areas
Generalized anxiety disorder
The clinical file supporting Selank's registration as a medicine in Russia rests principally on human trials in patients with generalized anxiety disorder (GAD). Zozulya and colleagues published a clinical study reporting anxiolytic effects in GAD patients, with a profile characterized as comparable to benzodiazepines in terms of anxiolysis, but without sedation, cognitive dulling, or evidence of dependence on cessation (Zozulya et al., 2008).
These trials are genuinely human clinical data — a rarity in the research peptide space — but the publications are primarily in Russian-language journals, and independent Western replication has not occurred.
Cognitive performance under stress
Research from the Myasoedov group has examined effects on cognitive function under conditions of psychological stress, reporting that Selank administration was associated with preservation of attention, memory, and decision-making performance in stress paradigms (Semenova et al., 2009).
Gene expression studies
Kolomin and colleagues have published a series of papers examining the transcriptomic footprint of Selank administration in rat brain tissue. These studies report broad and coordinated shifts in gene expression — including genes involved in neurotransmission, plasticity, and inflammation — rather than isolated single-target effects (Kolomin et al., 2010).
Cytokine balance research
Uchakina and colleagues have published studies examining cytokine modulation under Selank administration, reporting effects on the balance of Th1 / Th2 cytokines and on interleukin expression profiles (Uchakina et al., 2008).
Comparison to benzodiazepines
A distinctive theme in the Selank literature is the comparison to benzodiazepines. Published work reports that in behavioral anxiety models Selank produces comparable effect sizes, but without the sedation, motor impairment, or discontinuation phenomena that complicate benzodiazepine use (Kozlovskaya et al., 2003).
Clinical status in Russia
Selank is registered in the Russian Federation as a prescription medicine under the brand Selank 0.15% nasal spray, with generalized anxiety disorder as an approved indication. Registration dates to 2009, and the compound has been on the Russian pharmaceutical market since then (Myasoedov et al., 2015).
This is a meaningful distinction. Most of the compounds discussed in the peptide research community have no approved medical status anywhere. Selank does — in one jurisdiction, with one indication, under one regulatory framework.
Regulatory status outside Russia
Outside the Russian Federation, Selank is not approved as a medicine by the European Medicines Agency, the MHRA in the United Kingdom, the FDA in the United States, or any comparable regulator. It has no authorized therapeutic indication in those jurisdictions. Legally, in markets where it is available at all, it circulates as a research chemical for laboratory and in-vitro research purposes only.
Researchers in the English-speaking scientific community who have followed Selank tend to note the unusual situation in which a compound is simultaneously a registered pharmaceutical in one country and an unregistered research chemical everywhere else.
Current state of evidence
A sober view of the Selank literature must distinguish what has been studied from what has been established in the English-language peer-reviewed record.
- Substantial Russian human clinical data. Russian clinical trials supporting the generalized anxiety disorder indication are real and publicly documented, but largely in Russian-language journals.
- Limited Western peer-reviewed translation. A number of mechanistic and preclinical papers have appeared in English-language journals, but the full clinical file has not been systematically translated or replicated.
- Preclinical rodent research is extensive. Behavioral, immunological, and gene-expression studies in rats from the Myasoedov / Kolomin school form a coherent body of work.
- No regulatory approval outside Russia. Selank has no authorized therapeutic indication in the EU, UK, or US.
- Research chemical status outside Russia. In other markets it is sold strictly as a research chemical for in-vitro and laboratory research purposes only.
What the research does not show
Being explicit about what is not in the literature is as important as cataloging what is.
- No Western-run randomized controlled trials. The human clinical evidence base is Russian, not replicated by independent Western groups.
- No approved indication outside generalized anxiety disorder. Even in Russia, the registered indication is narrow; claims beyond GAD are not supported by the regulatory file.
- Long-term safety outside the registered Russian use is uncharacterized. Years-long follow-up data for populations outside the approved Russian indication does not exist in the peer-reviewed literature.
- Mechanism is not fully understood. The proposed mechanisms are hypotheses with varying levels of experimental support.
- Optimal non-Russian dosing is not established. The dose-finding work behind the registered Russian formulation does not automatically generalize.
Delivery format notes
The registered Russian pharmaceutical formulation is an intranasal spray at 0.15% concentration. The intranasal route is a deliberate design choice: small regulatory peptides are poorly absorbed orally and are frequently degraded in systemic circulation, but the nasal mucosa offers a route by which small amounts of peptide can reach the central nervous system with relatively short transit times (Gusev et al., 2018).
In the research peptide market outside Russia, lyophilized Selank is available as a laboratory reagent. Published literature on stability and handling describes standard peptide practice: freeze-dried storage, reconstitution in bacteriostatic or sterile water for research work, and refrigerated handling of solutions.
This article is a summary of published research. At no point should it be read as instruction for human use. Outside the Russian Federation, Selank is not an approved medicine. There is no established Western human protocol in the peer-reviewed literature. Even the Russian registered use is narrow in indication, population, and dose.